Viridian Therapeutics, Inc. VRDN NASDAQ

Viridian Therapeutics, Inc. (VRDN) reported total assets of $899.42M and total liabilities of $177.25M for fiscal year 2025, resulting in total equity of $722.17M.

The company held $874.65M in cash and short-term investments. Total debt stood at $50.69M, with net debt of $-161.69M. The Debt-to-Equity (D/E) ratio was 0.07 (conservative).

Current ratio is 12.65, indicating strong short-term liquidity. Interest coverage is -73.4x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (62/100) — Total assets $899.42M and equity $722.17M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.07 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$152.54

+3.76%

PCVX

Vaxcyte, Inc.

$60.45

-3.68%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

CYTK

Cytokinetics, Incorporated

$65.37

-1.48%

NUVL

Nuvalent, Inc.

$104.75

-0.26%

MRUS

Merus N.V.

$90.00

+0.00%

PTGX

Protagonist Therapeutics, Inc.

$105.44

+0.69%